H.C. Wainwright Initiates Coverage on SINTX Technologies with Buy Rating, Highlighting Silicon Nitride Platform Opportunity
April 23, 2026
Independent analyst coverage underscores SINTX’s transition to a commercial-stage biomaterials company, citing its silicon nitride technology, recent FDA clearance and first human implant, and a scalable platform strategy across orthopedics and adjacent healthcare markets.
Recent News
- Collaboration with Quest Diagnostics to expand kidneyintelX.dkd TM testing in the United States
- Utah Business Innovation Awards Summit Recap
- Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
- Co-Diagnostics Expands Vector Smart® Customer Reach with First International Installation in USAF Base
- Rep. Celeste Maloy Tours BIOS, Neurotech Innovation
- U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam for Pediatric Patients with Tourette Syndrome
